<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01219049</url>
  </required_header>
  <id_info>
    <org_study_id>09-1144</org_study_id>
    <nct_id>NCT01219049</nct_id>
  </id_info>
  <brief_title>L-Tyrosine Supplementation in Patients With Fibromyalgia</brief_title>
  <official_title>L-Tyrosine Supplementation in Patients With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients in the study, who have a diagnosis of fibromyalgia, will be randomly assigned to
      take the amino acid L-tyrosine or placebo (blank pill) for 3 weeks. They will fill out
      questionnaires about their symptoms and see if they have any improvement. The investigators
      hypothesis is that taking tyrosine will help alleviate the symptoms of fibromyalgia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fibromyalgia is a chronic pain syndrome with few treatment options available. The amino-acid
      L-tyrosine is the precursor for norepinephrine in the central nervous system (CNS).
      Norepinephrine in the CNS has important roles in pain and mood modulation and descending
      inhibition of pain pathways. By giving the precursor L-tyrosine in high doses we believe that
      we can increase levels of norepinephrine in the CNS. To study this question we designed a
      randomized blinded pilot study of 30 patients. Patients are randomly assigned to one of 3
      groups (placebo, tyrosine 1000mg/day, and tyrosine 2000mg/day.) for 3 weeks. Patients then
      complete the Brief Pain Inventory (BPI) daily and the Fibromyalgia impact questionnaire (FIQ)
      on day 1 and day 21. Patients also complete a drug diary. They are monitored weekly for
      progress during the study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to FDA comments, changes required unavailable resources. There are no results for this
    study.
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score</measure>
    <time_frame>daily for 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>FIQ Score</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>FIQ Score</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Tyrosine 1000 mg / day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 1000 mg tyrosine per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tyrosine 2000 mg / day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 2000 mg tyrosine per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tyrosine</intervention_name>
    <description>1000 mg / day</description>
    <arm_group_label>Tyrosine 1000 mg / day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tyrosine</intervention_name>
    <description>2000 mg / day</description>
    <arm_group_label>Tyrosine 2000 mg / day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of fibromyalgia

          -  Pain greater than 4/10

          -  Age greater than 18

        Exclusion Criteria:

          -  Pregnant

          -  Age less than 18
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Mazzeffi, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diet</keyword>
  <keyword>Fibromyalgia</keyword>
  <keyword>Pain</keyword>
  <keyword>Drug</keyword>
  <keyword>Amino-acid</keyword>
  <keyword>Fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

